QuidelOrtho Corporation (LON:0A55)
Market Cap | 1.45B |
Revenue (ttm) | 2.14B |
Net Income (ttm) | -277.08M |
Shares Out | n/a |
EPS (ttm) | -4.12 |
PE Ratio | n/a |
Forward PE | 11.06 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 2 |
Average Volume | 177 |
Open | 43.09 |
Previous Close | 43.64 |
Day's Range | 43.09 - 43.50 |
52-Week Range | 29.91 - 69.67 |
Beta | n/a |
RSI | 49.59 |
Earnings Date | Jul 30, 2025 |
About QuidelOrtho
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease,... [Read more]
Financial Performance
In 2024, QuidelOrtho's revenue was $2.78 billion, a decrease of -7.17% compared to the previous year's $3.00 billion. Losses were -$2.05 billion, 20216.8% more than in 2023.
Financial numbers in USD Financial StatementsNews

QuidelOrtho Strengthens Leadership Team With Appointments of Senior Vice Presidents for Global Quality and Clinical & Regulatory Affairs
New executives bring deep expertise to elevate quality and accelerate innovation across global operations SAN DIEGO , July 7, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company"...
QuidelOrtho to discontinue Savanna platform development

QuidelOrtho Announces Strategy to Accelerate Growth in Molecular Diagnostics
―Company Intends to Acquire LEX Diagnostics Upon U.S. FDA Clearance― ―Company Plans to Discontinue Savanna® Platform Development― ―Company Reaffirms Full Year 2025 Financial Guidance ― ―Company to Hos...

QuidelOrtho to Participate in Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs ...

Global Preeclampsia Diagnostics Market to Exhibit Growth at a CAGR of ~4% by 2032 | DelveInsight
New York, USA, May 14, 2025 (GLOBE NEWSWIRE) -- Global Preeclampsia Diagnostics Market to Exhibit Growth at a CAGR of ~4% by 2032 | DelveInsight The expansion of the preeclampsia diagnostics market is...
SA analyst downgrades: QDEL, AMCX, PLYM, DAY

QuidelOrtho: Stagnant Growth Means Best To Avoid (Rating Downgrade)
QuidelOrtho's stock jumped after Q1 2025 earnings beat, but long-term growth remains weak. Check out why QDEL stock is downgraded to hold.
Quidelortho sees $30M-$40M tariff impact offset, maintains 2025 guidance

QuidelOrtho Corporation (QDEL) Q1 2025 Earnings Call Transcript
QuidelOrtho Corporation (NASDAQ:QDEL) Q1 2025 Results Conference Call May 7, 2025 5:00 PM ET Company Participants Juliet Cunningham - Vice President, Investor Relations Brian Blaser - President and C...

QuidelOrtho Reports First Quarter 2025 Financial Results
SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care setting...

QuidelOrtho to Report First Quarter 2025 Financial Results
SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company”) or (“QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care setti...

QuidelOrtho® Introduces Results Manager™ System
SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”) announces the availability of the QuidelOrtho® Results Manager™ System, an informatics solution designed to address t...

QuidelOrtho to Participate in the 46th Annual Raymond James Institutional Investor Conference
SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (NASDAQ: QDEL) (“QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs ...
QuidelOrtho: Growth Struggles And Negative GAAP Earnings Continue To Disinterest Investors
T. Rowe Price Investment Management, Inc. Increases Stake in QuidelOrtho Corp
T. Rowe Price Investment Management, Inc. Increases Stake in QuidelOrtho Corp
Rubric Capital Management LP Increases Stake in QuidelOrtho Corp
Rubric Capital Management LP Increases Stake in QuidelOrtho Corp
QuidelOrtho (QDEL) Stock Moves on Earnings Beat
QuidelOrtho (QDEL) Stock Moves on Earnings Beat

Why QuidelOrtho Stock Bounced More Than 4% Higher Today
QuidelOrtho Corp (QDEL) Q4 2024 Earnings Call Highlights: Navigating Revenue Declines and ...
QuidelOrtho Corp (QDEL) Q4 2024 Earnings Call Highlights: Navigating Revenue Declines and Strategic Growth Initiatives
QuidelOrtho projects $2.6B-$2.81B revenue for 2025 supported by cost savings and margin expansion

QuidelOrtho Corporation (QDEL) Q4 2024 Earnings Call Transcript
QuidelOrtho Corporation (NASDAQ:QDEL) Q4 2024 Results Conference Call February 12, 2025 5:00 PM ET Company Participants Juliet Cunningham - Vice President, Investor Relations Brian Blaser - President...
QuidelOrtho 2025 EPS, revenue guidance ranges include consensus

QuidelOrtho Reports Fourth Quarter and Full-Year 2024 Financial Results
SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care setting...
QuidelOrtho Corp (QDEL) Announces Preliminary Fourth Quarter 2024 Revenue Results
QuidelOrtho Corp (QDEL) Announces Preliminary Fourth Quarter 2024 Revenue Results
QuidelOrtho announces preliminary Q4 2024 revenue in range of $702 million to $707 million
QuidelOrtho expects Q4 2024 revenues to exceed consensus estimates. Non-respiratory revenue projected at $561-563 million.